Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $197.8152W HIGH $495.55
Volume
959.45 K
Value Traded
305.53 M
Short % Float
5.39%
+5.82%Week
-6.43%1 Month
-19.23%3 Month
-30.13%6 Month
+110.45%5 Year
+4,776.23%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
31.13 B
EPS (TTM)
6.04
P/E Ratio
38.53
Ent. Value
27.83 B
Total Shares
133.74 M
Float Shares
133.38 M
Insiders
0.32%
Institutions
100.52%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ALNY Catalyst Timeline
Dated clinical, regulatory and corporate events for Alnylam Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Alnylam Pharmaceuticals, Inc.
810Total events
18Upcoming
307Tier-1 (high impact)
2014 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Oral PresentationVutrisiranApprovedPresentation
Cardiac Presentation and Treatment Response by Sex in Patients with Transthyretin Amyloidosis
ATTRsource ↗
▲Oral PresentationVutrisiranApprovedPresentation
Alnylam presents new data on AMVUTTRA at ESC Congress 2026
Transthyretin-Amyloidose (ATTR)source ↗
▲Oral PresentationVutrisiranApprovedPresentation
Late-breaking oral presentation of HELIOS-B prespecified subgroup analysis by baseline tafamidis use at ESC Congress 2026
ATTR-CMsource ↗
▲Poster PresentationVutrisiranApprovedPresentation
Pooled analysis across four Phase 3 studies of vutrisiran and patisiran presented at ESC Congress 2026
ATTR-CMsource ↗
▲Oral PresentationZilebesiranPresentation
Oral presentation of KARDIA-3 subgroup analysis at ESC Congress 2026
uncontrolled hypertensionsource ↗
▲PublicationVutrisiranApprovedPresentation
HELIOS-B subgroup analysis simultaneously published in Journal of the American College of Cardiology
ATTR-CMsource ↗
▲Poster PresentationZilebesiranPresentation
New subgroup analysis from KARDIA-3 Phase 2 study of zilebesiran presented at ESC Congress 2026
uncontrolled hypertensionsource ↗
▲Subgroup AnalysisVutrisiranApprovedClinical Data
Post hoc HELIOS-B analysis shows 25% less decline in intrinsic capacity and 52% reduction in risk of decline with vutrisiran
ATTR-CMsource ↗
▲Safety Data UpdateVutrisiranApprovedClinical Data
Post hoc HELIOS-B safety analysis shows fewer adverse events with vutrisiran versus placebo across populations
ATTR-CMsource ↗
▲Pooled AnalysisVutrisiranApprovedClinical Data
Pooled analysis of 1,402 patients shows consistent treatment effects of RNAi-powered TTR silencing across sexes
ATTR-CM and hATTR-PNsource ↗
▲Subgroup AnalysisZilebesiranClinical Data
KARDIA-3 post hoc subgroup analysis shows greater SBP reductions with zilebesiran in patients on background diuretic
uncontrolled hypertensionsource ↗
●RWE DataClinical Data
Real-world evidence shows higher extra-cardiac burden in ATTR-CM patients versus matched controls
ATTR-CMsource ↗
◆Oral PresentationPresentation
Amylo'ExTTRa: Exploring Extra-Cardiac Manifestations in Patients with ATTR-CM Using a French National Health Data System
ATTR-CMsource ↗
●Quarterly UpdateCorporate
Alnylam reports Q2 2026 financial results and recent period progress
●Oral PresentationPresentation
Alnylam highlights neuroscience progress at AAIC 2026
neurological diseasessource ↗
▲Partnership / LicenseCorporate
Komodo expands strategic partnership with Alnylam to scale AI-powered intelligence platform
▲Partnership / LicenseCorporate
GENESIS Pharma expands strategic commercial collaboration with Alnylam to Scandinavian countries
▲Partnership / LicenseCorporate
GENESIS Pharma expands strategic commercial partnership with Alnylam to Nordic region
▲Partnership / LicenseCorporate
Alnylam and Inceptive form strategic AI collaboration to accelerate RNAi therapeutic discovery
▲Oral PresentationVutrisiranApprovedPresentation
Neue Datenanalysen zu Vutrisiran bei ATTR-CM auf Heart Failure 2026 präsentiert
ATTR-CMsource ↗
▲Oral PresentationVutrisiranApprovedPresentation
Pooled analysis of over 25,000 patient-years of safety data for TTR-silencing RNAi therapies presented
ATTR-CMsource ↗
●Trial InitiationVutrisiranApprovedTrial
DemonsTTRate study design presented; expected to enroll >2,000 patients with up to 5 years follow-up
ATTR-CMsource ↗
◆Oral PresentationVutrisiranApprovedPresentation
Treatment with Transthyretin-Lowering RNA Interference Therapeutics is Not Associated with Ocular or Other Clinical Events Due to Vitamin A Reduction: Pooled Analysis of Vutrisiran and Patisiran Data
ATTR-CMsource ↗
◆Oral PresentationVutrisiranApprovedPresentation
Design and Rationale of DemonsTTRate: A Global, Long-Term Observational Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
ATTR-CMsource ↗
◆Oral PresentationVutrisiranApprovedPresentation
Presentatie nieuwe analyses op Heart Failure 2026
ATTR-CMsource ↗
▲Enrollment UpdateNucresiranTrial
Enrollment in TRITON-CM proceeding faster than anticipated; target expanded to ~1,750 patients
ATTR-CMsource ↗
▲Oral PresentationVutrisiranApprovedPresentation
New analyses from HELIOS-B presented at ACC Annual Scientific Session
ATTR-CMsource ↗
▲Partnership / LicenseCorporate
Entered research collaboration with Tenaya Therapeutics for cardiovascular targets
cardiovascular diseasessource ↗
▲Oral PresentationZilebesiranPresentation
Additional Phase 2 results for zilebesiran presented at ACC
hypertensionsource ↗
▲Trial InitiationALN-2232Trial
Initiated Phase 1 trial of ALN-2232 targeting ACVR1C for obesity
obesity and weight managementsource ↗
●NDA SubmissioncemdisiranFiledRegulatory Filing
Regeneron submitted NDA to FDA for cemdisiran in gMG
generalized myasthenia gravissource ↗
▲Product LaunchVutrisiranApprovedPost-Market
One year since U.S. launch of AMVUTTRA for ATTR-CM
ATTR-CMsource ↗
▲Oral PresentationVutrisiranApprovedPresentation
New data presented at ACC.26 for vutrisiran in ATTR-CM
ATTR-CMsource ↗
▲Oral PresentationZilebesiranPresentation
New data presented at ACC.26 for zilebesiran in hypertension
Hypertensionsource ↗
▲Partnership / LicenseCorporate
Strategic collaboration with Viz.ai to advance ATTR-CM care
ATTR-CMsource ↗
◆R&D DayPresentation
Investor webinar marking one-year anniversary of AMVUTTRA approval in ATTR-CM
▲Partnership / LicenseCorporate
Alnylam and Tenaya Therapeutics enter collaboration to identify novel genetic targets for heart disease
cardiovascular diseasessource ↗
◆Oral PresentationPresentation
Alnylam presentation at TD Cowen 46th Annual Health Care Conference
▲Other Regulator MilestoneVutrisiranApprovedEx-US Regulatory
Positive recommendation from Canada's Drug Agency (CDA) for public reimbursement of AMVUTTRA for ATTR-CM
cardiomyopathy in adult patients with wild-type or hereditary transthyretin-mediated amyloidosissource ↗
◆Oral PresentationPresentation
Management presentation at 44th Annual J.P. Morgan Healthcare Conference
▲Enrollment CompleteMivelsiranTrial
Completed enrollment in cAPPricorn-1 Phase 2 trial in CAA
cerebral amyloid angiopathysource ↗
Past FDA Catalysts and PDUFA Decisions
How ALNY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | Mivelsiran | Phase 1 interim results | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
B71 / 100
Pipeline Score
$8.5B
Pipeline Value
$19.3B
Commercial Value
Fair Value
Valuation Signal
21
Drugs Scored
0.7x
rNPV / MCap
Top 4%
Mid Cap(rank 27 of 660)
Percentile Rank
Alnylam Pharmaceuticals, Inc. holds a solid B-grade pipeline (71/100), with $10.0B risk-adjusted pipeline value, led by ALN-4324 in Type 2 Diabetes Mellitus (T2DM) (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $4.8B x 4.0 = $19.3B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Amvuttra | $3.4B | $1.3B | +153.4% |
| GIVLAARI | $325M | $284M | +14.6% |
| OXLUMO | $206M | $173M | +19.2% |
| ONPATTRO | $110M | $208M | -47.4% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALN-4324 Small moleculeNCT06845202 | Type 2 Diabetes Mellitus (T2DM) | Phase 2 | ACTIVE NOT_RECRUITING | 129 | Aug 31, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every ALNY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Vutrisiran | ATTR-CM | Phase 3 | 2026-05-12 | significantly reduced the risk of all-cause mortality and recurrent cardiovascular (CV) events compared with placebo; slowing the progressive decline in SBP observed over timeRead More | New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease BurdenRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SUPRAN BRYANOfficer (EVP, CLO and Secretary) | Sell | -1,758 12,807 held | $226.88 | 10/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ALNY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 3.6 % | 248.35 M | 825.00 K | 65% ( 325.00 K) |
ALNY Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ALNY ranks across every disease it competes in
Competitive Position is a premium feature
See how ALNY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialALNY News
ALNYAMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM
Alnylam Pharmaceuticals has launched the AMVUTTRA® (vutrisiran) ‘Play by Play’ initiative, aimed at educating the public about transthyretin-mediated amyloidosis (ATTR-CM). This initiative features stories from former professional athletes and their care teams to highlight the often-missed signs of the condition. The goal is to promote early recognition of symptoms for better patient care.
Read more →ALNY▲ +8.7%on this news
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Alnylam Pharmaceuticals has announced that its management will present company overviews at two upcoming investor conferences. The Wells Fargo 21st Annual Healthcare Conference is scheduled for September 8, 2026, and the Morgan Stanley 24th Annual Global Healthcare Conference will take place on September 14, 2026. Both events will feature live audio webcasts.
Read more →ALNYAlnylam präsentiert auf dem ESC Congress 2026 neue Daten, die die Wirksamkeit des RNAi-basierten TTR-Silencing bei verschiedenen ATTR-CM-Patientengruppen und in verschiedenen Behandlungsumgebungen belegen
Alnylam Pharmaceuticals presented new data at the ESC Congress 2026, showcasing the effectiveness of RNAi-based gene silencing in cardiovascular diseases. The findings reinforce the clinical profile of AMVUTTRA (Vutrisiran) in patients with Transthyretin Amyloidosis (ATTR) across different treatment contexts. This marks a significant advancement in the treatment of ATTR.
Read more →ALNYSamenvatting: Alnylam presenteert nieuwe gegevens op het ESC-congres 2026 en legt de nadruk op de effectiviteit van RNAi-gebaseerde TTR-silencing bij verschillende ATTR-CM-patiëntengroepen
Alnylam Pharmaceuticals has presented new data at the ESC Congress 2026, highlighting the effectiveness of RNAi-based TTR-silencing in various groups of ATTR-CM patients. This presentation underscores the company's commitment to advancing RNAi therapies for cardiovascular diseases. The findings are expected to contribute significantly to the treatment landscape for these patients.
Read more →ALNYResumen: Alnylam presenta nuevos datos en el Congreso 2026 de la ESC que refuerzan la eficacia en el silenciamiento de la transtiretina mediante interferencia de ARN en poblaciones de pacientes y entornos de tratamiento de miocardiopatía amiloide por trans...
Alnylam Pharmaceuticals presented new data at the 2026 ESC Congress, demonstrating the effectiveness of RNA interference in silencing transthyretin. This research focuses on patient populations and treatment settings for transthyretin amyloid cardiomyopathy. The findings support Alnylam's position as a leader in RNA interference therapies.
Read more →ALNYRiassunto: Alnylam presenta nuovi dati al Congresso ESC 2026, rafforzando l'efficacia del silenziamento della transtiretina (TTR) basato sulla tecnologia RNAi nelle popolazioni di pazienti affetti da ATTR-CM e nei diversi contesti terapeutici
Alnylam Pharmaceuticals has announced new data at the ESC 2026 Congress, showcasing the effectiveness of RNAi-based silencing in treating cardiovascular diseases, particularly in patients with ATTR-CM. This presentation reinforces the company's leadership in RNAi therapies and their potential impact on patient care. The findings contribute to the ongoing dialogue in cardiovascular treatment advancements.
Read more →ALNYAlnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
Alnylam Pharmaceuticals presented new data at the ESC Congress 2026, highlighting the effectiveness of RNAi-powered silencing in treating cardiovascular diseases. The results strengthen the clinical profile of AMVUTTRA® (vutrisiran) in various patient populations and treatment settings for transthyretin amyloidosis (ATTR). This reinforces the drug's potential across different manifestations of the disease.
Read more →ALNYAlnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026
Alnylam Pharmaceuticals will present new clinical and real-world data at the ESC Congress 2026. The data will focus on their transthyretin-mediated amyloidosis (ATTR) and hypertension programs. This presentation aims to reinforce the efficacy of their RNAi-powered therapies. The congress is scheduled for August 28-31, 2026, in Munich, Germany.
Read more →ALNY▼ -28.3%on this news
Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress
Alnylam Pharmaceuticals reported significant financial results for Q2 2026, highlighting a historic achievement of over $1 billion in quarterly product revenues. The company emphasized its ongoing advancements in the RNAi therapeutics sector and expressed optimism about future growth. This performance marks a pivotal moment in Alnylam's business trajectory.
Read more →ALNYAlnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results
Alnylam Pharmaceuticals will report its second quarter 2026 financial results on July 30, 2026, before market opening. The management team will discuss these results and provide future expectations during a conference call scheduled for 8:30 am ET on the same day. This event highlights the company's ongoing commitment to transparency and stakeholder engagement.
Read more →ALNYAlnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
Alnylam Pharmaceuticals presented significant advancements in its neuroscience programs at the AAIC 2026. The company emphasized the potential of RNA interference (RNAi) therapeutics to meet the needs of patients suffering from neurological diseases. Notably, the investigational therapeutic Mivelsiran targets amyloid precursor protein, which could have implications for treatment.
Read more →ALNYKomodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform
Komodo has expanded its strategic partnership with Alnylam Pharmaceuticals to enhance its AI-powered intelligence platform. This collaboration aims to leverage advanced analytics to improve healthcare outcomes. The details of the expansion and its implications for both companies were not specified in the article.
Read more →ALNYAlnylam to Host Tenth “RNAi Roundtable” Webcast Series
Alnylam Pharmaceuticals is set to host the tenth installment of its 'RNAi Roundtable' webcast series. This event aims to engage stakeholders in discussions about RNA interference technology and its applications. Further details about the webcast, including speakers and topics, have not been provided in the article.
Read more →ALNYGENESIS Pharma erweitert strategische Vertriebspartnerschaft mit Alnylam Pharmaceuticals bei RNAi-Therapeutika auf skandinavische Länder
GENESIS Pharma has expanded its strategic distribution partnership with Alnylam Pharmaceuticals to include Scandinavian countries for RNAi therapeutics. This partnership aims to enhance the availability of innovative treatments in the region. The collaboration reflects a commitment to advancing RNAi technology in new markets.
Read more →ALNYRiassunto: GENESIS Pharma espande ad alcuni paesi scandinavi la collaborazione commerciale strategica con Alnylam Pharmaceuticals in materia di terapie RNAi
GENESIS Pharma has expanded its strategic commercial collaboration with Alnylam Pharmaceuticals to include certain Scandinavian countries. This partnership focuses on RNAi therapies, enhancing the reach and availability of these treatments in the region. The collaboration aims to leverage both companies' strengths in the biopharmaceutical sector.
Read more →ALNYSamenvatting: GENESIS Pharma breidt strategisch commercieel partnerschap met Alnylam Pharmaceuticals voor RNAi-therapieën uit naar de Scandinavische regio
GENESIS Pharma is expanding its strategic commercial partnership with Alnylam Pharmaceuticals to include RNAi therapies in the Scandinavian region. This move aims to enhance the availability of innovative treatments in this market. The partnership reflects a growing interest in RNAi therapies and their potential impact on healthcare in Scandinavia.
Read more →ALNYGENESIS Pharma Expands Strategic Commercial Partnership with Alnylam Pharmaceuticals for RNAi Therapeutics to the Nordic Region
GENESIS Pharma has expanded its strategic partnership with Alnylam Pharmaceuticals to enhance the commercialization of RNAi therapeutics in the Nordic region. This collaboration aims to leverage both companies' strengths to improve patient access to innovative treatments. The partnership reflects a commitment to advancing RNAi technology in new markets.
Read more →ALNYAlnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
Alnylam Pharmaceuticals has announced a strategic collaboration with Inceptive to leverage artificial intelligence in the discovery of RNA interference (RNAi) therapeutics. This partnership is expected to enhance the efficiency and effectiveness of developing new RNAi-based treatments. The collaboration highlights the growing trend of integrating AI in biopharmaceutical research.
Read more →ALNYAlnylam Issues 2025 Corporate Responsibility Report
Alnylam Pharmaceuticals has released its 2025 Corporate Responsibility Report. The report outlines the company's commitment to sustainability and ethical practices. However, specific details regarding the content of the report are not provided in the article.
Read more →ALNYHeart Failure 2026: Neue Datenanalysen belegen robusten und konsistenten klinischen Nutzen von Vutrisiran als Erstlinien-Behandlungsoption für ATTR-CM-Patientenpopulationen – auch bei hoher Krankheitslast
The article discusses new data analyses regarding Vutrisiran as a first-line treatment option for patients with ATTR-CM. It highlights the clinical benefits observed in patient populations with high disease burden. However, specific details about the data or analyses are not provided.
Read more →About Alnylam Pharmaceuticals, Inc.
Headquarters675 WEST KENDALL STREET, CAMBRIDGE, MA, 02142
Founded2002
BIOPHARMAWATCH ELITE PLUS
Trade the next ALNY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime